Captor Capital Valuation

Q: What is the Fair Price of NMV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

NMV (€0.45) is trading below our estimate of [[fair value]] (€24.62)

Is NMV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NMV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NMV (€0.45) is trading below our estimate of fair value (€24.62)

Significantly Below Fair Value: NMV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NMV?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for NMV. This is calculated by dividing NMV's market cap by their current preferred multiple.
What is NMV's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CA$5.56m

NMV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does NMV's PS Ratio compare to its peers?

The above table shows the PS ratio for NMV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	13.8x
B8FK Biofrontera	0.5x	n/a	€15.1m
0RX Redx Pharma	13.3x	-37.6%	€65.0m
HIGH Cantourage Group	37.9x	35.4%	€63.0m
2FJ0 Pierrel	3.4x	n/a	€92.8m
NMV Captor Capital	0.2x	n/a	€5.6m

Price-To-Sales vs Peers: NMV is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (13.8x).

Price to Earnings Ratio vs Industry

How does NMV's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: NMV is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Pharmaceuticals industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is NMV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NMV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NMV's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.